RESEARCH USE ONLY - Not for human or veterinary use. Supplied for lawful in vitro research and qualified laboratory investigation only. QUALITY - Peptide catalogue items are specified at ≥99% purity with batch documentation. Store lyophilised powders as directed before reconstitution. COMPLIANCE - You are responsible for lawful purchase, possession, and use in your jurisdiction, including institutional and safety requirements. SAFE HANDLING - Use trained personnel, appropriate PPE, and aseptic technique. Do not ingest, inject, or use outside a controlled research setting. POLICIES & ORDERS - Shipping, returns, and research-use terms apply to every order. Read our Research Use Policy and footer legal links before buying.

GLP-SM 5mg lyophilised vial - for research purposes only

Purity

≥99%

Format

Lyophilised

Documentation

CoA on request

Storage

−20°C

GLP-1 Agonist · Metabolic

GLP-SM — Semaglutide (GLP-1 Agonist)

Long-acting GLP-1 receptor agonist · supplied as 5mg lyophilised powder

≥99% Purity

CoA Available

GLP-SM is a long-acting, acylated GLP-1 receptor agonist with high structural homology to endogenous human GLP-1. Albumin binding and amino-acid substitutions confer an extended half-life, making it a widely used reference in GLP-1 receptor biology, metabolic disease models, and related cardiovascular research.

Size - 5mg

Available as 5mg lyophilised vial only.

£29.99

View Cart →

What is GLP-SM?

GLP-SM is a synthetic analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 cleavage and prolonged circulation. As a GLP-1 receptor agonist it models glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central satiety signalling - with an extended duration of action suited to weekly-style dosing protocols in research.

Product Code

GLP-SM

Presentation

5mg vial

Receptor Target

GLP-1R

Mechanism

GLP-1 Receptor Agonist

Molecular Weight

~4,114 Da

Half-Life (approx.)

~7 Days

Research Background

This compound class has one of the largest published evidence bases among GLP-1 receptor agonists. Representative research themes include:

Glycaemic control: Documented HbA1c and fasting glucose improvements in controlled trials.
Body composition: Substantial weight reduction in obesity study populations at higher doses.
Cardiovascular markers: Outcomes trials reporting MACE reduction in high-risk cohorts.
Hepatic fat: Reductions in steatosis markers in NAFLD/NASH research models.
Neuroscience: Ongoing investigation of GLP-1R pathways in neurodegeneration models.

Technical Specifications

Appearance

White Lyophilised Powder

Purity

≥99%

Format

Lyophilised (Freeze-Dried)

Reconstitution

Bacteriostatic Water

Storage (Lyophilised)

−20°C, protected from light

Storage (Reconstituted)

2–8°C, use within 28 days

Shelf Life

24 months (lyophilised)

CoA

Available on Request

Frequently Asked Questions

How does GLP-SM achieve its long half-life?

DPP-4–resistant substitutions and reversible albumin binding via an acyl chain extend plasma half-life to roughly one week in clinical-style protocols.

How does GLP-SM compare to GLP-TZ?

GLP-SM is a GLP-1 monoagonist. GLP-TZ co-activates GIP receptors; many studies report stronger metabolic endpoints with dual agonism than with GLP-1 alone.

Is a Certificate of Analysis provided?

Yes. A CoA documenting batch purity and specifications is available for every batch on request.